Sufentanil transdermal - DURECT

Drug Profile

Sufentanil transdermal - DURECT

Alternative Names: Chronogesic; EN 3270; TRANSDUR™ sufentanil

Latest Information Update: 27 Jul 2015

Price : $50

At a glance

  • Originator DURECT Corporation
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 27 Jul 2015 Discontinued - Phase-II for Pain in USA (Transdermal)
  • 20 May 2014 Sufentanil transdermal is available for licensing as of 20 May 2014 (http://www.durect.com/wt/durect/page_name/partner)
  • 17 Feb 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top